|HEPI.OB Reports Safety Findings, Extends PAZ Study|
|Tuesday, 25 August 2009 08:04|
Health Enhancement Products, Inc. (OTC:HEPI) (HEPI.OB) is a nutraceutical company engaged in the development of dietary supplements, food additives, and ingredients which are created entirely from pure, all-natural compounds. The Company's premier product is ProAlgaZyme (PAZ), a liquid product drawn from living algae grown in purified water through a process whereby the water in which the algae is grown is drawn off, filtered, and bottled as PAZ (now marketed with a new name and look as LiquidMD).
On 7/15/09, HEPI.OB announced preliminary results of its study to confirm the efficacy of its PAZ bioactive compound in managing LDL and HDL cholesterol levels. The WSU study confirmed that the PAZ organic compound was found to reduce LDL (bad) cholesterol levels from 131.7mg/dL to 79.57mg/dL and improve HDL (good) cholesterol from 105.27mg/dL to 138.67mg/dL in test animals (hamsters).
On 8/25/09, HEPI.OB (in conjunction with Wayne State University, WSU) announced that the WSU research team, led by Smiti Gupta, Ph.D., assistant professor of Nutrition & Food Sciences noted the absence of any detectable inflammation in liver samples taken from the test subjects in its preliminary study findings. This is encouraging, given that other means of controlling cholesterol such as multi-billion dollar selling statin drugs (e.g. Lipitor, Zocor, Crestor) may have a negative effect on liver function.
As a result of positive results obtained thus far, the Company announced the expansion of the current WSU study, adding a therapeutic component to the study to establish the efficacy of specific, isolated PAZ filtrates in managing cholesterol and inflammation over a longer period of time, as well as a review of toxicity, safety and dosing parameters and HEPI expects to provide an update on this process in the coming weeks (with a 9/21/09 estimate for this entry).
Click here for my overview article on HEPI from early August and below is an outline of upcoming catalysts and milestones that I expect to occur over the near to intermediate term (a few weeks to six months):
(1) updates from the expanded WSU study to provide longer term data on the Company's isolated PAZ filtrates in managing cholesterol and inflammation, as well as a review of toxicity, safety and dosing parameters
(2) the publication of a scientific paper derived from the extended WSU study findings by Dr. Gupta
(3) the isolation and identification of the bioactive molecule(s) in PAZ as part of the extended WSU study
(4) the announcement of a global licensing deal with a major packaged food company such as GIS, K, KFT, or Nestle to created functional food products such as cereals that contain the bioactive molecule(s) isolated from PAZ once longer term safety and efficacy data is obtained from human studies
Disclosure: Long HEPI.OB